- cafead Aug 07, 2022 at 11:42: PM
via Gilead Sciences will acquire U.K.-based startup MiroBio, which is developing antibody drugs for autoimmune disorders, in a $405 million deal announced Thursday.
MiroBio sprouted from a University of Oxford research laboratory run by professors Simon Davis and Richard Cornall. Its approach focuses on checkpoint receptors, proteins that help to regulate the immune system.
article source
MiroBio sprouted from a University of Oxford research laboratory run by professors Simon Davis and Richard Cornall. Its approach focuses on checkpoint receptors, proteins that help to regulate the immune system.
article source